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S St tu ud dy y D De es si ig gn n:: The serum levels of transforming growth factor-beta 1 (TGF-β 1), tissue inhibitor of matrix metallopro-
teinase-1 (TIMP-1) and TIMP-2 were measured by enzyme-linked immunosorbent assay. 
P Pu ur rp po os se e:: To compare the serum levels of TGF-β 1, TIMP-1 and TIMP-2 between patients with lumbar spinal stenosis and
disc herniation. 
O Ov ve er rv vi ie ew w o of f L Li it te er ra at tu ur re e:: It has been reported that increased concentrations of TGF-β 1, TIMP-1 and TIMP-2 in the liga-
mentum flavum might be a possible pathogenesis for ligamentum flavum hypertrophy in spinal stenosis. However, it is not
determined whether this phenomenon in spinal stenosis is a local or systemic problem. 
M Me et th ho od ds s:: The concentrations of TGF-β 1, TIMP-1 and TIMP-2 were quantitatively analyzed by ELISA in the ligamentum
flavum and serum of patients with lumbar spinal stenosis (n=16) and disc herniation (n=16). The thickness of ligamentum
flavum was measured on axial T1-weigted magnetic resonance image. The biochemical and radiological results were com-
pared for the two conditions. 
R Re es su ul lt ts s:: The thickness of the ligamentum flavum was larger in patients with spinal stenosis compared with that with disc
herniation (p=0.001). The mean concentrations of TGF-β 1, TIMP-1, and TIMP-2 in the ligamentum flavum were signifi-
cantly higher in patients with spinal stenosis than those with disc herniation (all, p<0.05). However, the difference in serum
levels of TGF-β 1 (p=0.464), TIMP-1 (p=0.146) and TIMP-2 (p=0.794) was not significant between the lumbar spinal steno-
sis and disc herniation patients. 
C Co on nc cl lu us si io on ns s:: Despite increased levels of TGF-β 1, TIMP-1, and TIMP-2 in the ligamentum flavum of spinal stenosis patients
compared to disc herniation patients, the serum levels of TGF-β 1, TIMP-1 and TIMP-2 were very similar in both groups.
These results indicate that the role of TGF-β 1, TIMP-1 and TIMP-2 on hypertrophy of the ligamentum flavum in spinal
stenosis patients is a local phenomenon, not systemic.
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Introduction
Hypertrophy of the ligamentum flavum is one character-
istic of degenerative lumbar spinal stenosis, which can
cause neurogenic claudication secondary to compression of
the cauda equina or nerve roots. Degenerative changes sec-
ondary to the aging process and mechanical stress such as
instability have been reported to be attributed to hypertro-
phy of the ligamentum flavum of lumbar spinal stenosis
1-5.
The authors of this study previously reported
6,7 on what was
thought to be the first’ biochemical studies showing
increased concentrations of transforming growth factor-beta
1 (TGF-β 1), tissue inhibitor of matrix metalloproteinase-1
(TIMP-1) and TIMP-2 in hypertrophied ligamentum flavum
of patients with lumbar spinal stenosis compared to patients
with lumbar disc herniation. Additionally, TGF-β 1, TIMP-1
and TIMP-2 were positively stained on fibroblasts of theligamentum flavum, indicating that these proteins are syn-
thesized by these cells. One issue that remained at the com-
pletion of the original two studies was the systemic implica-
tions of these proteins. We believe that it would be impor-
tant to determine whether increased concentrations of TGF-
β 1, TIMP-1 and TIMP-2 in patients with spinal stenosis is a
local or systemic phenomena. The purpose of the current
study was to compare the serum levels of TGF-β 1, TIMP-1
and TIMP-2 between patients with lumbar spinal stenosis
and those with disc herniation.
Materials and Methods
Sixteen patients who had undergone decompressive
surgery for neurogenic claudication due to single level lum-
bar spinal stenosis were included in this study. Twelve
patients were female and four were male. The mean age of
the patients was 60.2 years (range, 41~75 years) and the
mean duration of symptoms between onset and operation
was 14.7 weeks (range, 1~23 weeks). The operated levels
were 10 at L4-L5, 5 at L5-S1, and 1 at level L3-L4. Patients
with degenerative spondylolisthesis were excluded from the
study. As control, sixteen patients who had undergone pos-
terior open discectomy for radiating pain due to single level
lumbar disc herniation were selected for this study. Ten
patients were male and six were female. The mean age of
the patients in this group was 32.4 years (range, 21~42
years), which was significantly younger than that of the
patients with spinal stenosis (p<0.001). Patients with a his-
tory of diabetes mellitus, pulmonary disease, cardiovascular
disease, and renal disease were excluded from this study. 
1. Measurement of ligamentum flavum thickness 
For each patient, an axial T1-weighted magnetic reso-
nance image (repetition time, 600 msec; echo time, 30
msec) was obtained at the facet joint level of the lesion
using a 1.5-tesler unit (Siemens, Somatoplus, Germany).
The maximum thickness of the ligamentum flavum was
traced using the manual cursor technique and computed
automatically by the installed software in the magnetic reso-
nance imaging scan. All of the radiographic analyses were
independently performed by two experienced spine sur-
geons who were uninvolved in the patients’ care. Each
observer independently measured the thickness of the liga-
mentum flavum two times and the average of the four mea-
surements was used as the final thickness. 
2. Extraction and quantification of protein from liga-
mentum flavum 
Thirty-two ligamentum flavum specimens were obtained
from all patients. A total of 100 mg of the ligamentum
flavum tissue was homogenized with phosphate-buffered
saline at 3,000 rpm (Tissue Tearor/Biospec products,
Racine, WI/model 985-370). Then centrifugation was per-
formed with 15,000 rpm at 4℃ for 30 minutes and super-
natant was obtained. Quantification of protein was per-
formed according to Bradford’s method using a protein
assay kit (Catalog no. 500-0006; Biorad, Hercules, CA,
USA), and optical density was measured at 595 nm by spec-
trophotometer (Ultrospec 3000; Pharmacia Biotech, Cam-
bridge, UK). Ligamentum flavum tissue extracts containing
100 μ g of protein were used for measurement of TGF-β 1,
TIMP-1 and TIMP-2.
3. Local levels of TGF-β 1, TIMP-1 and TIMP-2 by
ELISA assay 
Ligamentum flavum tissue extracts containing 100 μ g of
protein were quantitatively analyzed for TGF-β 1, TIMP-1 and
TIMP-2 following the manufacturer’s recommendations,
using an enzyme-linked immunosorbent assay (ELISA) kit
with antibodies that recognized human TGF-β 1, TIMP-1 and
TIMP-2 (R & D Systems, Minneapolis, MN, USA). For cali-
bration we used human recombinant TGF-β 1, TIMP-1 and
TIMP-2 provided by the supplier to construct a standard curve
and to obtain absolute values. TGF-β 1, TIMP-1 and TIMP-2
values were normalized to 100 μ g protein in each well.
4. Serum levels of TGF-β 1, TIMP-1 and TIMP-2 by
ELISA assay 
Following the manufacturer’s instructions, ten cc of blood
samples were obtained from the patients. Then serum was
separated by centrifugation at 3,000 rpm for 15 minutes.
TGF-β 1, TIMP-1 and TIMP-2 concentrations were mea-
sured twice for each sample using an ELISA kit with anti-
bodies that recognized human TGF-β 1, TIMP-1 and TIMP-
2 (R & D Systems). The average of the two measurements
was used as the final concentration. For calibration, we used
human recombinant TGF-β 1, TIMP-1 and TIMP-2 provided
by the supplier to construct a standard curve and to obtain
absolute values. 
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An independent sample T-test was used to investigate the
difference in patients’ age, ligamentum flavum thickness,
local and serum levels of TGF-β 1, TIMP-1 and TIMP-2
between the lumbar spinal stenosis and disc herniation
patients. A p value of less than 0.05 was considered statisti-
cally significant. 
Results
1. Thickness of ligamentum flavum 
The mean thickness of the ligamentum flavum was 5.34
±0.97 mm in patients with lumbar spinal stenosis and 2.54
±0.32 mm in patients with lumbar disc herniations. The
difference was significant (p=0.001).
2. Local levels of TGF-β 1, TIMP-1 and TIMP-2  
The mean concentration of TGF-β 1 in the ligamentum
flavum was 127.43±53.62 pg/mL in the lumbar stenosis
patients and 39.21±14.27 pg/mL in the  herniation patients
(p<0.05). The mean concentration of TIMP-1 in the liga-
mentum flavum was 7.92±2.35 ng/mL in the stenosis
patients and 3.56±1.29 ng/mL in the herniation patients
(p<0.05). The mean concentration of TIMP-2 in the liga-
mentum flavum was 14.28±5.31 ng/mL in stenosis patients
and 7.53±3.97 ng/mL in the herniation patients (p<0.05).
3. Serum levels of TGF-β 1, TIMP-1 and TIMP-2  
The mean concentration of TGF-β 1 in serum was 32.84±
16.37 pg/mL in the stenosis patients and 35.56±12.92
pg/mL in the herniation patients (p=0.464). The mean con-
centration of TIMP-1 in serum was 13.90±0.68 ng/mL in
the stenosis and 13.94±0.93 ng/mL in the herniation
patients (p=0.146). The mean concentration of TIMP-2 in
serum was 18.63±0.35 ng/mL in the stenosis patients and
18.92±0.38 ng/mL in the herniation patients (p=0.794).
Discussion
TGF-β 1 is known as a multifunctional cytokine involved
in cellular proliferation, differentiation, and synthesis of
extracellular matrix proteins
8-14. It is also thought to play
important roles in several physiological and pathological
conditions such as wound repair, hypertrophic burn scars,
and fibrotic disorders of the liver, kidney, heart, and lungs.
TIMPs, inhibitors of MMPs, are believed to regulate the
integrity and homeostasis of the extracellular matrix. Espe-
cially, increased expressions of TIMP-1 and TIMP-2 have
been implicated in increased fibrosis of a wide variety of
human organs, including the liver, kidney, lungs, and heart,
by reduced MMPs activities
15-19. Decreased MMPs activities
results in impairment of matrix degradation, which has been
demonstrated to be associated with fibrotic diseases.
In previous studies
6,7, the concentrations of TGF-β 1,
TIMP-1 and TIMP-2 produced by fibroblasts might have
been attributed to hypertrophy of the ligamentum flavum in
patients with lumbar spinal stenosis via autocrine or
paracrine fashions. However, there have been no studies to
determine whether an increased concentration of TGF-β 1,
TIMP-1 and TIMP-2 in patients with spinal stenosis is a
local or systemic phenomena. We therefore undertook this
study to compare the serum levels of TGF-β 1, TIMP-1 and
TIMP-2 between patients with lumbar spinal stenosis and
disc herniation.   
The thickness of the ligamentum flavum and the age of
spinal stenosis patients were significantly higher compared
to the disc herniation patients in this study. The local levels
of TGF-β 1, TIMP-1 and TIMP-2 were significantly higher
in the ligamentum flavum of patients with lumbar spinal
stenosis than those with disc herniation. Furthermore, we
found that serum levels of TGF-β 1, TIMP-1 and TIMP-2
were very similar in both groups with no significant differ-
ence. These results suggest that the role of TGF-β 1, TIMP-1
and TIMP-2 on hypertrophy of the ligamentum flavum in
lumbar stenosis patients is not a systemic phenomenon but
rather a local one. In addition, we excluded from the study
patients with any history of diabetes mellitus, pulmonary
disease, cardiovascular disease, and renal disease that could
have affected the serum levels of these proteins. Therefore,
serum levels of TGF-β 1, TIMP-1 and TIMP-2 measured in
the current study can be used as normal values of these pro-
teins in the serum. However, we should be cautious in inter-
preting these results because of the sex distribution differ-
ences between two groups.
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